Tapewire

Nasdaq · USD

IMVT

Immunovant, Inc.

Export transactions ↓
Tapewire entity
3632
SEC CIK
0001764013
Parsed reports
357

Last 12 months

Inside the activity.

1 purchase rows · 60 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202502
Dec 202516
Jan 202603
Feb 202603
Mar 202601
Apr 202608
May 202607
Jun 2026010
Jul 2026012
Aug 202602
Sep 202601
Oct 202605

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
April 01, 2025 Filed Apr 3, 2025 20:48 UTC
Barnett Eva ReneeChief Financial Officer
GrantStock Option (right to buy) · Derivative 125,180 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001764013-25-000051 · wk-form4_1743713294.xml · derivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,180

Underlying: Common Stock · 125,180 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:48 UTC
Barnett Eva ReneeChief Financial Officer
GrantCommon Stock 88,878 $0.00 $0.00
Disclosure

SEC source: 0001764013-25-000051 · wk-form4_1743713294.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 410,830

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:46 UTC
Salzmann PeterDirector · Chief Executive Officer
GrantStock Option (right to buy) · Derivative 374,395 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001764013-25-000049 · wk-form4_1743713207.xml · derivative · entry 2

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,395

Underlying: Common Stock · 374,395 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:46 UTC
Salzmann PeterDirector · Chief Executive Officer
GrantCommon Stock 265,820 $0.00 $0.00
Disclosure

SEC source: 0001764013-25-000049 · wk-form4_1743713207.xml · nonDerivative · entry 1

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,214,606

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:44 UTC
Pande AtulDirector
GrantStock Option (right to buy) · Derivative 7,600 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001764013-25-000047 · wk-form4_1743713068.xml · derivative · entry 3

Pande Atul · CIK 0001643071 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,600

Underlying: Common Stock · 7,600 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:44 UTC
Pande AtulDirector
GrantCommon Stock 16,188 $0.00 $0.00
Disclosure

SEC source: 0001764013-25-000047 · wk-form4_1743713068.xml · nonDerivative · entry 1

Pande Atul · CIK 0001643071 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,851

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:41 UTC GrantStock Option (right to buy) · Derivative 7,600 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001764013-25-000043 · wk-form4_1743712868.xml · derivative · entry 2

Fromkin Andrew J. · CIK 0001341896 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,600

Underlying: Common Stock · 7,600 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:41 UTC GrantCommon Stock 16,188 $0.00 $0.00
Disclosure

SEC source: 0001764013-25-000043 · wk-form4_1743712868.xml · nonDerivative · entry 1

Fromkin Andrew J. · CIK 0001341896 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,101

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:37 UTC
Torti FrankDirector
GrantStock Option (right to buy) · Derivative 93,599 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001764013-25-000039 · wk-form4_1743712656.xml · derivative · entry 2

Torti Frank · CIK 0001647805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,599

Underlying: Common Stock · 93,599 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest in substantially equal quarterly installments over two years measured from the date of the award, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:37 UTC
Torti FrankDirector
GrantCommon Stock 199,365 $0.00 $0.00
Disclosure

SEC source: 0001764013-25-000039 · wk-form4_1743712656.xml · nonDerivative · entry 1

Torti Frank · CIK 0001647805 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 835,039

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. These units will vest in equal quarterly installments over two years measured from the date of the award, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:43 UTC GrantStock Option (right to buy) · Derivative 7,600 $0.00 Strike: $15.20 $0.00
Disclosure

SEC source: 0001764013-25-000045 · wk-form4_1743712974.xml · derivative · entry 2

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,600

Underlying: Common Stock · 7,600 shares

Expires 2035-04-01

F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:43 UTC GrantCommon Stock 16,188 $0.00 $0.00
Disclosure

SEC source: 0001764013-25-000045 · wk-form4_1743712974.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,773

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 20:18 UTC SaleCommon Stock 1,384 $19.96 $27,624.64
Disclosure

SEC source: 0001764013-25-000034 · wk-form4_1741724319.xml · nonDerivative · entry 2

Fromkin Andrew J. · CIK 0001341896 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,913

F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.91 - $20.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 20:18 UTC SaleCommon Stock 6,616 $19.52 $129,144.32
Disclosure

SEC source: 0001764013-25-000034 · wk-form4_1741724319.xml · nonDerivative · entry 1

Fromkin Andrew J. · CIK 0001341896 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 93,297

F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.91 - $19.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 16:06 UTC
Macias William L.Chief Medical Officer
SaleCommon Stock 2,055 $20.86 $42,867.30
Disclosure

SEC source: 0001764013-25-000032 · wk-form4_1740171953.xml · nonDerivative · entry 1

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 357,353

F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 - $21.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 21:05 UTC
Barnett Eva ReneeChief Financial Officer
SaleCommon Stock 2,814 $20.86 $58,700.04
Disclosure

SEC source: 0001764013-25-000031 · wk-form4_1740171904.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 321,952

F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 - $21.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 21:04 UTC
Salzmann PeterDirector · Chief Executive Officer
SaleCommon Stock 15,439 $20.86 $322,057.54
Disclosure

SEC source: 0001764013-25-000030 · wk-form4_1740171852.xml · nonDerivative · entry 1

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 948,786

F1 · shares: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on February 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 - $21.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 22, 2025 Filed Jan 24, 2025 16:22 UTC
Geffner MichaelChief Medical Officer
SaleCommon Stock 2,657 $23.59 $62,678.63
Disclosure

SEC source: 0001764013-25-000018 · wk-form4_1737753717.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,314

F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on January 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Read SEC document
January 22, 2025 Filed Jan 24, 2025 21:23 UTC
Stout Jay SChief Technology Officer
SaleCommon Stock 2,195 $23.59 $51,780.05
Disclosure

SEC source: 0001764013-25-000019 · wk-form4_1737753791.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,991

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on January 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 16:07 UTC
Macias William L.Chief Medical Officer
SaleCommon Stock 19 $24.19 $459.61
Disclosure

SEC source: 0001764013-25-000015 · wk-form4_1737148045.xml · nonDerivative · entry 4

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 359,408

F4 · shares: On June 11, 2021, the holder was granted 18,674 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on June 15, 2021, of which 1,167 of these RSUs vested on January 13, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 16:07 UTC
Macias William L.Chief Medical Officer
SaleCommon Stock 387 $23.81 $9,214.47
Disclosure

SEC source: 0001764013-25-000015 · wk-form4_1737148045.xml · nonDerivative · entry 3

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 359,427

F4 · shares: On June 11, 2021, the holder was granted 18,674 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on June 15, 2021, of which 1,167 of these RSUs vested on January 13, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 16:07 UTC
Macias William L.Chief Medical Officer
SaleCommon Stock 94 $24.19 $2,273.86
Disclosure

SEC source: 0001764013-25-000015 · wk-form4_1737148045.xml · nonDerivative · entry 2

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 359,814

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 16:07 UTC
Macias William L.Chief Medical Officer
SaleCommon Stock 1,883 $23.81 $44,834.23
Disclosure

SEC source: 0001764013-25-000015 · wk-form4_1737148045.xml · nonDerivative · entry 1

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 359,908

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 21:05 UTC
Barnett Eva ReneeChief Financial Officer
SaleCommon Stock 109 $24.19 $2,636.71
Disclosure

SEC source: 0001764013-25-000014 · wk-form4_1737147952.xml · nonDerivative · entry 2

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 324,766

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 21:05 UTC
Barnett Eva ReneeChief Financial Officer
SaleCommon Stock 2,189 $23.81 $52,120.09
Disclosure

SEC source: 0001764013-25-000014 · wk-form4_1737147952.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 324,875

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 21:04 UTC
Salzmann PeterDirector · Chief Executive Officer
SaleCommon Stock 415 $24.19 $10,038.85
Disclosure

SEC source: 0001764013-25-000013 · wk-form4_1737147867.xml · nonDerivative · entry 2

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 964,225

F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,239 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 15, 2025 Filed Jan 17, 2025 21:04 UTC
Salzmann PeterDirector · Chief Executive Officer
SaleCommon Stock 8,352 $23.81 $198,861.12
Disclosure

SEC source: 0001764013-25-000013 · wk-form4_1737147867.xml · nonDerivative · entry 1

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 964,640

F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,239 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 13, 2025 Filed Jan 15, 2025 21:36 UTC
Roivant Sciences Ltd.Director · 10% owner
PurchaseCommon Stock, $0.0001 par value per share 16,845,010 $20.00 $336,900,200.00
Disclosure

SEC source: 0001140361-25-001188 · form4.xml · nonDerivative · entry 1

Roivant Sciences Ltd. · CIK 0001635088 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,650,341

Read SEC document
January 08, 2025 Filed Jan 10, 2025 21:12 UTC
Barnett Eva ReneeChief Financial Officer
SaleCommon Stock 4,105 $24.10 $98,930.50
Disclosure

SEC source: 0001764013-25-000004 · wk-form4_1736543549.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 327,064

F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.91 - $24.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 21:11 UTC
Salzmann PeterDirector · Chief Executive Officer
SaleCommon Stock 5,105 $24.10 $123,030.50
Disclosure

SEC source: 0001764013-25-000003 · wk-form4_1736543457.xml · nonDerivative · entry 1

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 972,992

F1 · shares: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,282 of these RSUs vested on January 1, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.91 - $24.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
December 16, 2024 Filed Dec 18, 2024 22:02 UTC
Van Tuyl ChristopherChief Legal Officer
GrantStock Option (right to buy) · Derivative 137,446 $0.00 Strike: $27.63 $0.00
Disclosure

SEC source: 0001764013-24-000204 · wk-form4_1734559363.xml · derivative · entry 2

Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,446

Underlying: Common Stock · 137,446 shares

Expires 2034-12-16

F2 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2019 Equity Incentive Plan. The shares underlying the option will vest as to 25% of the shares on December 16, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
December 16, 2024 Filed Dec 18, 2024 22:02 UTC
Van Tuyl ChristopherChief Legal Officer
GrantCommon Stock 109,956 $0.00 $0.00
Disclosure

SEC source: 0001764013-24-000204 · wk-form4_1734559363.xml · nonDerivative · entry 1

Van Tuyl Christopher · CIK 0001779707 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,956

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on December 16, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 21:22 UTC
Pande AtulDirector
SaleCommon Stock 7,750 $28.54 $221,185.00
Disclosure

SEC source: 0001764013-24-000200 · wk-form4_1733347352.xml · nonDerivative · entry 1

Pande Atul · CIK 0001643071 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,663

F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.03 - $29.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 21:20 UTC SaleCommon Stock 5,425 $28.54 $154,829.50
Disclosure

SEC source: 0001764013-24-000199 · wk-form4_1733347209.xml · nonDerivative · entry 1

Hughes Douglas J. · CIK 0001710863 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,585

F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.05 - $28.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 20, 2024 Filed Nov 22, 2024 16:11 UTC
Macias William L.Chief Medical Officer
SaleCommon Stock 3,353 $25.45 $85,333.85
Disclosure

SEC source: 0001764013-24-000195 · wk-form4_1732309904.xml · nonDerivative · entry 1

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 361,791

F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 20, 2024 Filed Nov 22, 2024 21:09 UTC
Barnett Eva ReneeChief Financial Officer
SaleCommon Stock 4,174 $25.45 $106,228.30
Disclosure

SEC source: 0001764013-24-000194 · wk-form4_1732309782.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,169

F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 20, 2024 Filed Nov 22, 2024 21:12 UTC
Levine Mark S.Chief Legal Officer
SaleCommon Stock 3,650 $25.45 $92,892.50
Disclosure

SEC source: 0001764013-24-000196 · wk-form4_1732309949.xml · nonDerivative · entry 1

Levine Mark S. · CIK 0001617236 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 319,228

F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 20, 2024 Filed Nov 22, 2024 21:08 UTC
Salzmann PeterDirector · Chief Executive Officer
SaleCommon Stock 16,692 $25.45 $424,811.40
Disclosure

SEC source: 0001764013-24-000193 · wk-form4_1732309693.xml · nonDerivative · entry 1

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 978,097

F1 · shares: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
November 18, 2024 Filed Nov 20, 2024 22:15 UTC
Gloria MelanieChief Operating Officer
GrantStock Option (right to buy) · Derivative 137,446 $0.00 Strike: $25.51 $0.00
Disclosure

SEC source: 0001764013-24-000188 · wk-form4_1732140934.xml · derivative · entry 2

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,446

Underlying: Common Stock · 137,446 shares

Expires 2034-11-18

F2 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2019 Equity Incentive Plan. The shares underlying the option will vest as to 25% of the shares on November 18, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
November 18, 2024 Filed Nov 20, 2024 22:15 UTC
Gloria MelanieChief Operating Officer
GrantCommon Stock 109,956 $0.00 $0.00
Disclosure

SEC source: 0001764013-24-000188 · wk-form4_1732140934.xml · nonDerivative · entry 1

Gloria Melanie · CIK 0001973838 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,956

F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on November 18, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Read SEC document
October 23, 2024 Filed Oct 25, 2024 16:23 UTC
Geffner MichaelChief Medical Officer
SaleCommon Stock 3,189 $29.53 $94,171.17
Disclosure

SEC source: 0001764013-24-000179 · wk-form4_1729887814.xml · nonDerivative · entry 1

Geffner Michael · CIK 0002007249 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,971

F1 · shares: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on October 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 23, 2024 Filed Oct 25, 2024 20:21 UTC
Stout Jay SChief Technology Officer
SaleCommon Stock 2,740 $29.53 $80,912.20
Disclosure

SEC source: 0001764013-24-000178 · wk-form4_1729887693.xml · nonDerivative · entry 1

Stout Jay S · CIK 0001702969 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,186

F1 · shares: On April 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on October 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 23, 2024 Filed Oct 25, 2024 20:25 UTC
Levine Mark S.Chief Legal Officer
SaleCommon Stock 4,361 $29.53 $128,780.33
Disclosure

SEC source: 0001764013-24-000180 · wk-form4_1729887897.xml · nonDerivative · entry 1

Levine Mark S. · CIK 0001617236 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 322,878

F1 · shares: On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,937 of these RSUs vested on October 19, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 - $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 16, 2024 Filed Oct 18, 2024 16:30 UTC
Macias William L.Chief Medical Officer
SaleCommon Stock 561 $28.79 $16,151.19
Disclosure

SEC source: 0001764013-24-000173 · wk-form4_1729283415.xml · nonDerivative · entry 2

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 365,144

F3 · shares: On June 11, 2021, the holder was granted 18,674 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on June 15, 2021, of which 1,167 of these RSUs vested on October 13, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 16, 2024 Filed Oct 18, 2024 16:30 UTC
Macias William L.Chief Medical Officer
SaleCommon Stock 2,627 $28.79 $75,631.33
Disclosure

SEC source: 0001764013-24-000173 · wk-form4_1729283415.xml · nonDerivative · entry 1

Macias William L. · CIK 0001864280 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 365,705

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 16, 2024 Filed Oct 18, 2024 20:31 UTC
Salzmann PeterDirector · Chief Executive Officer
SaleCommon Stock 9,095 $28.79 $261,845.05
Disclosure

SEC source: 0001764013-24-000174 · wk-form4_1729283466.xml · nonDerivative · entry 1

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 994,789

F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,240 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 16, 2024 Filed Oct 18, 2024 20:28 UTC
Levine Mark S.Chief Legal Officer
SaleCommon Stock 2,860 $28.79 $82,339.40
Disclosure

SEC source: 0001764013-24-000172 · wk-form4_1729283330.xml · nonDerivative · entry 1

Levine Mark S. · CIK 0001617236 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 327,239

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 16, 2024 Filed Oct 18, 2024 20:27 UTC
Barnett Eva ReneeChief Financial Officer
SaleCommon Stock 3,271 $28.79 $94,172.09
Disclosure

SEC source: 0001764013-24-000171 · wk-form4_1729283253.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,343

F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 09, 2024 Filed Oct 11, 2024 20:04 UTC
Barnett Eva ReneeChief Financial Officer
SaleCommon Stock 5,162 $29.56 $152,588.72
Disclosure

SEC source: 0001764013-24-000166 · wk-form4_1728677055.xml · nonDerivative · entry 1

Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,614

F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on October 4, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.28 - $29.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 09, 2024 Filed Oct 11, 2024 20:02 UTC
Salzmann PeterDirector · Chief Executive Officer
SaleCommon Stock 4,460 $29.56 $131,837.60
Disclosure

SEC source: 0001764013-24-000165 · wk-form4_1728676955.xml · nonDerivative · entry 1

Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,003,884

F1 · shares: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on October 1, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.28 - $29.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.